Rossari Biotech Ltd (ROSSARI) Growth Catalysts - Q1 FY27 (Jun-26)
10 growth catalysts flagged by management, 1 new in the recent quarters, 1 no longer discussed.
Reported base: Revenue Rs. 697.2 crore, +28% YoY; EBITDA Rs. 80.6 crore, +18.7% YoY, 11.6% margin; PAT Rs. 35.1 crore, +4.5% YoY.
Growth catalysts
Thailand plant expansion
The ₹10–15 cr Thailand formulation plant is ramping up on textile chemicals; Mgmt plans to add AHN products and other HPPC molecules a few quarters down the line.
Quantum: Rs. 50 crore - Rs. 75 crore · Timeline: A few quarters down the line · Textile Specialty Chemicals · Geography
Discussed on the earnings calls of Jun-26, Mar-26, Dec-25.
Pharma business ramp-up
Mgmt targets customer and plant compliances by the end of Q2 or Q3 FY27, enabling ramp-up to close to Rs 30–50 cr revenue potential this year.
Quantum: Rs. 30 crore - Rs. 50 crore · Timeline: By the end of Q2 or Q3; this year · Pharma · New product
Discussed on the earnings calls of Jun-26, Mar-26.
8 more growth catalysts on the Stocksigma ELITE plan.
Guidance & timelines
- Pharma revenue potential: Close to Rs. 30 crore - Rs. 50 crore (Timeline: This year)
- EBITDA margin target: Around 15% at least (Timeline: In two years)
8 more guidance items on ELITE.